NewsBenzingaOPKO Biologics somministra la prima dose al primo paziente nel suo studio clinico di fase 1/2a su OPK-8801001 per il trattamento dell’acromegalia OPKO Biologics somministra la prima dose al primo paziente nel suo studio clinico di fase 1/2a su OPK-8801001 per il trattamento dell’acromegalia Benzinga 2026.10.27 12:07 (GMT+0) Open on Benzinga Other news What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday